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Progressive multifocal leukoencephalopathy (PML) is caused by JC polyomavirus (JCPyV). Because a
reciprocal relationship has been described between antibody levels to JCPyV and BK polyomavirus
(BKPyV), we performed a nested case control study with pre-diagnostic serum samples from HIV infected
subjects to examine the relationship between BKPyV capsid antibodies and the risk of PML. Serum
samples collected 0.5–2 years before PML diagnosis from 25 cases (66 samples) and 80 matched controls
(204 samples) were tested in ELISA for JCPyV, BKPyV type 1 and type 4 capsid antibodies. High levels of
BKPyV 1 and 4 antibodies were associated with a lower risk of PML (BKPyV 1 OR, 0.56, 95% CI, 0.35–0.89;
BKPyV 4 OR, 0.40, 95% CI, 0.24–0.0.67). Our study demonstrates that antibodies to BKPyV capsids are an
immunological marker of protection against development of PML. Further studies are needed to deﬁne
the mechanism.
& 2015 Elsevier Inc. All rights reserved.Introduction
Progressive multifocal leukoencephalopathy (PML) is a severe
demyelinating disorder of the central nervous system caused by
lytic infection of oligodendrocytes with JC polyomavirus (JCPyV)
(Brew et al., 2010). PML occurs on a background of conditions
associated with T-cell deﬁciencies (Viscidi and Shah, 2010). The
majority of cases reported in the past 3 decades have occurred in
human immunodeﬁciency virus (HIV) infected patients (Chris-
tensen et al., 2010). More recently, the immunomodulatory drug,
natalizumab, and less commonly other monoclonal antibodies
targeting immune modulatory antigens have been associated with
rare cases of PML (Rossi et al., 2015).
Exposure to JCPyV is common in the general population but
PML is a rare disease, even among patients at risk due to an
underlying predisposing condition. Thus, most individuals must be
protected against the development of PML. Protection is likely toBlalock Building Room 1105,
ax: þ1 410 955 3723.be immunologically mediated since all conditions associated with
PML involve an immunodeﬁciency state. However, the nature of
protective immunity is unknown. As a measure of exposure to
JCPyV, antibodies to the VP1 major capsid protein have been shown
to be a risk predictor for PML associated with natalizumab therapy
(Gorelik et al., 2010), and we have shown that JCPyV seropositivity
is associated with a non-signiﬁcant trend for increased risk of PML
in HIV-infected patients (Viscidi et al., 2011a). JCPyV is genetically
related to a second human polyomavirus, BK polyomavirus (BKPyV)
(Bennett et al., 2012). A negative correlation has been observed
between levels of antibody to JCPyV and BKPyV capsids (Kean et al.,
2009; Egli et al., 2009; Hamilton et al., 2000; Knowles et al., 2003).
This unexplained phenomenological observation lead us to hypo-
thesize that high levels of antibody to BKPyV will be a biomarker for
protection against the development of PML.
An opportunity to investigate pre-diagnostic markers is pro-
vided by prospective cohort studies of HIV infected subjects. We
performed a nested case control study, conducted within the
Multicenter AIDS Cohort Study (MACS), to examine whether
antibody to BKPyV capsids are predictors of the subsequent
diagnosis of PML. BKPyV genotypes are known to be serologically
distinct and the major genotypes circulating in human populations
F. Rossi et al. / Virology 485 (2015) 467–472468are types 1 and 4; therefore, we tested for antibody to the capsid
proteins of these two major serotypes (Pastrana et al., 2013).Fig. 1. Distribution of IgG absorbance values to BKPyV 1, BKPyV 4, and JCPyV
capsids in sera from PML cases and HIV disease matched controls at time intervals
before the diagnosis of PML. The summary statistics of each distribution are dis-
played in a box plot. The length of the box corresponds to the interquartile range
with the upper boundary of the box representing the 75th percentile and the lower
boundary the 25th percentile. The horizontal clear line in the box represents the
median value. The 10th and 90th percentiles are shown by the small bar at the end
of the line extending downward or upward, respectively, from the box. Each outlier
value is shown individually by a solid line. The number of outliers that is not dis-
played in the graph space is indicated at the top of each graph. The number of
samples contributing to each distribution is indicated at the bottom of the ﬁgure.Results
Demographic characteristics of cases and controls were similar
(Table 1). The two populations were matched for age, race/ethni-
city, intravenous drug use, average years on the study, and level of
CD4þ T-cells at entry into the study. Cases were more likely than
controls to have been smokers and had a lower median CD4þ
T-cell count at the time of PML diagnosis, but these differences did
not reach statistical signiﬁcance. Seven cases were excluded from
the study because plasma samples were not available during the
time interval of interest, 0.5–2 years prior to PML diagnosis. The
excluded cases had similar demographics characteristics to the
cases included in the study, with the exception that the excluded
cases were less likely to have been smokers (p¼0.01).
The distribution of IgG seroreactivity to BKPyV 1, BKPyV 4, and
JCPyV capsids in cases and controls during six-month time inter-
vals from 0.5 to 2 years prior to PML diagnosis is shown in Fig. 1. In
all three time intervals before PML, BKPyV 1 and BKPyV 4 IgG
levels were signiﬁcantly (po0.05) lower in cases than in controls,
indicating that a high BK antibody level is a biomarker for pro-
tection against the risk of developing PML. For example, 1–1.5
years prior to diagnosis, the median seroreactivity to BK serotype
1 and serotype 4 among cases was 0.186 optical density (OD) units
and 0.153 OD units, respectively, while the corresponding values
for controls were 0.443 OD units and 0.578 OD units, respectively.
Similar differences between cases and controls were observed 0.5–
1 year and 1.5–2 years before PML diagnosis. In contrast, JCPyV
antibody levels were higher among cases than controls, although
the difference was not statistically signiﬁcant. The strength of the
association was similar for all three 6-month time intervals indi-
cating that the relationship between the biomarkers and risk of
PML is stable up to 2 years before PML diagnosis.
Logistic regression analysis was performed in an univariate model
for BKPyV 1 and BKPyV 4 seroreactivity, and in Multivariate Models
for each biomarker after adjusting for age, CD4þ T-cell count, JCPyV
seroreactivity, and seroreactivity to the heterologous BKPyV serotype
(Multivariate Models 1 and 2) and after adjusting for all the variables
(Multivariate Model 3) (Table 2). In Multivariate Models 1 and 2, pre-
diagnostic BKPyV 1 and BKPyV 4 seroreactivity were signiﬁcantly
associated with a lower risk of subsequent development of PML, with
a BKPyV 1 odds ratio (OR) of 0.56 and 95% conﬁdence limits (CI) of
0.35–0.89, and a BKPyV 4 OR of 0.40 and 95% CI of 0.24–0.67. AfterTable 1
Characteristics of Study Populations.
Variable Cases in analysis (n¼25) Controls (n¼80) p-Valuea Cases excluded (n¼7) p-Valueb
Age, median (IQR) 39(36, 44) 41(36, 46) 0.575 46(37, 61) 0.202
Race/ethnicity, N (%) 0.281 0.395
White 24(96) 78(98) 6(86)
Black 0(0) 2(3) 1(14)
Other 1(4) 0(0) 0(0)
Ever IV drug use, N (%) 4(16) 9(11) 0.504 0(0) 0.552
Ever smoking, N (%) 21(84) 51(64) 0.083 2(29) 0.010
Years on study, median (IQR) 6.8(4.3, 8.6) 6.8(4.8, 9.3) 0.717 6(2.5, 12.0) 0.906
Calendar Yr Dx, median (IQR) 1992(1989, 1994) NA 1991(1989, 1997) 1.0
Entry CD4, median (IQR) 551(359, 643) 484(376, 636) 0.861 506(162, 579) 0.211
CD4 at Dx, median (IQR) 123(87, 199) 182(90, 280) 0.086 155(100, 252) 0.715
p-Values were obtained by non-parametric Wilcoxon test or Fisher exact test, as appropriate.
a Comparing cases and controls.
b Comparing 25 cases in analysis and 7 cases excluded from analysis.
Table 2
Odds Ratios (ORs)a and 95% Conﬁdence Intervals (CIs) from modelsb predicting PML.
Possible predictors Univariate model Multivariate Model 1 Multivariate Model 2 Multivariate Model 3
Log 2(BKPyV 1), per þ1.6 log 2 0.54(0.34, 0.85) 0.56(0.35, 0.89) – 0.75(0.41, 1.40)
Log 2(BKPyV 4), per þ1.4 log 2 0.42(0.26, 0.69) – 0.40(0.24, 0.67) 0.45(0.25, 0.83)
Age, per þ6.7 years 0.93(0.59, 1.49) 0.86(0.53, 1.41) 0.87(0.52, 1.45) 0.86(0.51, 1.43)
CD4 cell count, per þ180 cells 0.75(0.52, 1.08) 0.78(0.53, 1.14) 0.65(0.44, 0.97) 0.68(0.45, 1.03)
Log 2(JCPyV), per þ1.6 log 2 1.27(0.8, 2.01) 1.20(0.73, 1.96) 1.38(0.84, 2.26) 1.31(0.79, 2.18)
a ORs (95% CIs) were based on 1 standard deviation increase in all predictors in models.
b Logistic regression models using combined data from 0.5 to 2 years before PML diagnosis with general estimating equations to account for repeated measures.
Fig. 2. Distribution of percent BKPyV 4 seroreactivity blocked by pre-incubation
with BKPyV 4 VLP protein among 23 PML cases and 65 HIV disease matched
controls. Data are displayed in a box plot as described in the legend to Fig. 1.
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associated with a statistically signiﬁcant lower risk of subsequent
PML (OR, 0.45, 95% CI, 0.24–0.83) and BKPyV 1 seroreactivity was
associated with a lower, but non-signiﬁcant risk of PML (OR, 0.75, 95%
CI, 0.41–1.4). These data provide strong support for the value of
BKPyV serology, particularly seroreactivity to BKPyV 4 capsids, as a
pre-diagnostic marker for the risk of developing PML in patients with
human immunodeﬁciency virus infection. In an univariate model
restricted to the 7 histologically conﬁrmed cases of PML, BKPyV
4 seroreactivity was also signiﬁcantly associated with a lower risk of
subsequent PML (OR, 0.27, 95% CI, 0.09–0.86) and BKPyV 1 seror-
eactivity was associated with a lower, but non-signiﬁcant risk of PML
(OR, 0.48, 95% CI, 0.22–1.04).
Because the multivariate model adjusting for all variables high-
lighted the importance of BKPyV 4 seroreactivity, we investigated
the speciﬁcity of this reactivity by performing a competitive
inhibition assay. A reduction in BKPyV 4 seroreactivity by pre-
incubation of serum samples with BKPyV 4 VLP protein is evidence
for speciﬁcity of the reactivity, while failure to inhibit the reac-
tivity indicates that uncharacterized cross reactive antibodies are
responsible for the seroreactivity. The distribution of BKPyV
4 percent inhibition among cases and controls is shown in Fig. 2.
Mean percent inhibition of BKPyV 4 seroreactivity was greater in
serum samples from controls than cases with a median percent
inhibition of control and case serum samples of 59% and 29%,
respectively (non-parametric Wilcoxon test po0.001), indicating
that BKPyV 4 seroreactivity in control sera was more speciﬁc than
that in case sera. In a multivariate conditional logistic model,
percent BKPyV 4 inhibition after adjustment for age and CD4þ
T-cell count was associated with a lower risk of subsequent
development of PML (hazard ratio, 0.30, 95% CI, 0.12–0.71). Using
a conventional deﬁnition of speciﬁc seroreactivity of inhibitiongreater than 40%, 46 of 65 (71%) control serum samples as com-
pared to eight of 23 (35%) case serum samples were BKPyV
4 reactive (Fisher's exact, p¼0.005), showing the value of speciﬁc
BKPyV 4 seroreactivity as a biomarker for protection against PML.
To develop an analytical framework that would combine
information from the three antibody biomarkers and CD4þ T-cell
count into an algorithm to predict the risk of PML, we imple-
mented a classiﬁcation tree analysis. In this analysis data are
iteratively stratiﬁed into dichotomous categories to achieve the
optimal differentiation of cases from controls. The analytical
results are displayed as a tree-like structure with all data points
falling within terminal nodes. Ideally every node would have a
probability of 100% for classiﬁcation as a case or control. Where
probabilities are less than 100%, the node will contain a mixture of
cases and controls. For the classiﬁcation tree analysis we used the
average value across all 6-month time intervals for each variable
so the number of data points corresponds to the number of sub-
jects. As shown in the optimally pruned tree (Fig. 3), subjects were
initially stratiﬁed by BKPyV 4 seroreactivity greater or less than
0.140 OD units. Only 12 subjects had an OD value o0.140 and 10
of these subjects were cases, resulting in a terminal node with
a probability of being a case of 83%. The result highlights the
importance of a low BKPyV 4 antibody level for the risk of sub-
sequent PML. The remaining 93 subjects, which included 15 cases,
had a BKPyV 4 seroreactivity 40.140 OD units and could be fur-
ther stratiﬁed based on a CD4þ T-cell count greater or less than
336 cell per microliter. There were 29 subjects with a CD4þ T cell
count greater than 336 cells per microliter and all of them were
controls, resulting in a terminal node with 100% probability of
being a control. Of the remaining 64 subjects, including 15 cases,
stratiﬁcation based on a JCPyV antibody level greater or less than
0.56 OD units placed 11 cases in the group with the higher JCPyV
antibody level. Among the 28 subjects and 11 cases in this group,
9 of the 11 cases had a CD4þ T cell count above 195.5 cells per
microliter (and less than 336 cells per microliter as noted above),
resulting in a terminal node with a probability of being a case of
64%. Two cases fell in the group with a CD4þ T cell count less than
195.5 cells per microliter suggesting that a very low CD4þ T cell
count was not a primary determinant of risk in the subgroup of
subjects with a high JCPyV antibody level and CD4þ T cell count
below 336 cell per microliter. Among the 36 subjects with a JCPyV
antibody level less than 0.56 OD units the risk of being a case was
low (11%), but further stratiﬁcation into a group with a BKPyV
1 antibody level between 0.496 and 0.65 OD units resulted in a
terminal node with 5 subjects, 3 of whom were cases (probability
of being a case 60%). The results of a classiﬁcation analysis can
also be expressed as the proportion of data points that are mis-
classiﬁed. For our analysis 12 (11.4%) of 105 subjects were mis-
classiﬁed as either controls falling in terminal nodes categorized as
case or cases in control-designated terminal nodes.
Fig. 3. Classiﬁcation tree analysis predicting PML among 25 cases and 80 matched controls. Classiﬁcation tree analysis was performed by using Splus software. Predictors in
the analysis included CD4þ T-cell count, and BKPyV 1, BKPyV 4, and JCPyV OD values. The predictor and cut off used to stratify subjects is shown above the horizontal line
and the number of subjects and percentage that is cases is indicated below the line. Terminal nodes (vertical lines ending without further division) are labeled case or Ctrl
(control) based on a majority of classiﬁed subjects falling into that strata. For each terminal node, the number of subjects, percentage of cases, and absolute number of cases
is indicated.
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PML is always observed in the setting of cellular immunodeﬁ-
ciency. However, the incidence of PML among immunosuppressed
patients is low. Among HIV patients, the incidence of PML was
calculated between 3% and 7% before the advent of combined
antiretroviral therapy and has decreased in the current therapy era
(Cinque et al., 2009). The overall incidence of PML in patients
treated with natalizumab is 3.78 per 1000 (Kornek, 2015). Few
prognostic factors, other than immunosuppression, have been
identiﬁed to predict the risk of PML. In patients receiving natali-
zumab, prior immunosuppressive therapy, a longer duration of
natalizumab therapy, and JCPyV seropositivity, particularly high
levels of antibody, convey a risk of 1% as compared to less than
0.01% in seronegative individuals (Biogen Idec, 2015; Bloomgren
et al., 2012; Gorelik et al., 2010; Plavina et al., 2014). Among HIV
infected patients, JCPyV seropositivity is associated with a non-
signiﬁcant trend for increased risk of subsequent PML (Viscidi
et al., 2011a). The reason for the modest predictive value of JCPyV
serology in HIV patients as compared to natalizumab-associated
PML is unclear but may reﬂect an effect of immunosuppression on
antibody levels. We also cannot exclude the possibility that long
term storage of serum samples interfered with the performance of
the serological assay.
Our nested-case-control study of patients enrolled in MACS
provides evidence that higher levels of antibody to BKPyV capsids
are associated with a decreased risk of PML up to 2 years prior to
the clinical diagnosis.
Why should individuals with high levels of antibody to BKPyV
capsids be protected against PML? BKPyV and JCPyV are geneti-
cally closely related, with greater than 85% similarity in protein
sequences, raising the possibility of immunological cross protec-
tion. A direct protective role for antibody to BKPyV capsids is
highly unlikely because adsorption studies have shown there is no
serological cross reactivity between the capsid proteins of the
viruses (Viscidi and Clayman, 2006). Additionally, mechanismsinvolved in lysis of infected cells are more likely to be important in
control of reactivation of a latent or persistent viral infection.
Capsid antibodies could be a correlative marker for antibodies to
other JCPyV antigens that share cross reactive epitopes with the
corresponding BKPyV antigens. Studies with the animal poly-
omavirus SV40 have shown that antibodies to the large T antigen
can mediate lysis of SV40-transformed cells by a mechanism
involving antibody dependent cellular cytotoxicity ADCC (Bright
et al., 1994). Such a mechanism of BKPyV-mediated cross protec-
tion against JCPyV infection is possible, but to date ADCC resp-
onses to JCPyV and BKPyV large T antigen have not been investi-
gated. Capsid antibodies could also be a correlative marker for
cellular immunity. We speculate that cross reactive cellular
immunity may explain our ﬁndings. JCPyV-speciﬁc T-cell immu-
nity has been associated with a better outcome following the
diagnosis of PML (Khanna et al., 2009; Du Pasquier et al., 2004).
We performed a bioinformatics analysis of predicted HLA-A*02
epitopes in JCPyV and BKPyV large T antigen and capsid protein
amino acid sequences and found several putative T cell epitopes
with identical amino acid sequences (data not shown). Cross
reactive T cell epitopes in the major capsid proteins of BKPyV and
JCPyV have also been experimentally demonstrated (Li et al.,
2006). Additional indirect evidence for BKPyV cross protection
against JCPyV infection is provided by the observation that the
presence of one virus in the urine makes viruria with the other
virus less likely and co-detection of both viruses in urine is rare
(Cheng et al., 2011; Rossi et al., 2014). We also note that exposure
to BKPyV occurs earlier in life than exposure to JCPyV, as docu-
mented by age seroprevalence studies (Viscidi et al., 2011b). Prior
exposure to BKPyV might confer partial immunity to JCPyV,
resulting in a mild primary infection and low levels of serum
antibody to JCPyV capsids. In contrast, unprotected individuals
would have a severe primary JCPyV infection, resulting in high
levels of JCPyV capsid antibody and a future risk of PML. Irre-
spective of the mechanism of protection, we are unaware of
other examples where exposure to one virus is associated with
F. Rossi et al. / Virology 485 (2015) 467–472 471protection against disease with a genetically related virus, making
this a novel mechanism of disease prevention.
Our study has several limitations. It is not clear if the ﬁndings of
our study are applicable to patients with other immunodeﬁciency
states associated with PML or patients treated with natalizumab.
While the majority of cases in our study were diagnosed clinically
and without the aid of virological testing, the ﬁndings were
replicated in the subset of patients with a histologically conﬁrmed
diagnosis. Although the classiﬁcation tree analysis shows that
BKPyV serology together with other variables has utility for risk
prediction, these ﬁndings need to be conﬁrmed in an independent
cohort. In addition to BKPyV serotypes 1 and 4, there are two other
BKPyV serotypes. We cannot exclude cross reactivity in our ELISA
assay and thus we cannot attribute the risk of PML to a particular
serotype.Methods and materials
Study population
The MACS is an ongoing, prospective cohort study of HIV/AIDS
in homosexual and bisexual men in the United States (Detels et al.,
2012). Initial recruitment for the MACS began in April 1983 and up
to January 2001, a total of 2239 HIV-positive men have been
enrolled and 584 HIV-negative men at study entry have become
HIV-1 infected. Collectively, these men have contributed over
34,491 HIV-positive person-years of observation. The study was
approved by local ethical review boards, and written informed
consent was obtained from all participants.
Demographic and clinical data and plasma samples were col-
lected at follow-up visits every 6 months. A total of 32 patients
were diagnosed with PML between 1985 and 2000. Seven patients
were excluded from the present study because plasma samples
were not available during the time interval of interest, 0.5–2 years
prior to PML diagnosis. The time interval was selected based on
sample availability and the desire to evaluate biomarkers in a
clinically useful time frame. PML was diagnosed by histological
examination of brain tissue in 7 of 25 (28%), a combination of
radiographic and clinical signs in 8 (32%), radiology alone in 2 (8%),
and clinical diagnosis alone in 8 (32%) patients. Each case was
matched to three HIV seropositive participants, who did not
develop PML. Matching criteria were (1) CD4þ T-cell count (750
cells per microliter) at the study entry visit to account for duration
of HIV infection prior to entry into the study and (2) PML-free time
from baseline. Cases for which PML was the AIDS deﬁning event
were further matched to HIV-positive controls on rate of CD4þ
T-cell decline from baseline (750 cells per microliter per year). If
PML was not the AIDS-deﬁning event of a case, an HIV-positive
control was selected who had an AIDS-deﬁning event within one
calendar year of the AIDS-deﬁning event of the case and com-
parable PML-free time from AIDS. A total of 81 controls were
identiﬁed. The 25 cases contributed a total of 66 plasma specimens
with 16 (64%) cases providing three or more specimens. The 80
controls contributed a total of 204 plasma specimens with 52
(65%) controls providing three or more specimens.
Serological assays
To construct a virus-like particle (VLP) for a BKPyV genotype
4 strain, a recombinant baculovirus expressing a codon optimized
VP1 gene of BKPyV genotype 4 strain MMR-29 was constructed
and VLPs were puriﬁed from insect cells infected with the
recombinant virus using methods previously developed for pur-
iﬁcation of polyomavirus VLPs (Viscidi et al., 2003). A VLP-based
enzyme-linked immunosorbent assay (ELISA) was used to detectserum antibody to JCPyV, BKPyV genotype I and BKPyV genotype
4 capsids, as described previously, with minor modiﬁcations
(Viscidi et al., 2011a). A subset of serum samples was tested in a
competitive inhibition (blocking) ELISA assay to determine the
speciﬁcity of BKPyV 4 seroreactivity. Percent inhibition was cal-
culated as follows: optical density (OD) value of blocking VLP/OD
value of buffer control100.Statistical analyses
The distributions of characteristics in cases and controls were
compared by the Wilcoxon rank-sum test or chi-square test. The
distributions of JCPyV, BKPyV 1 and BKPyV 4 seroreactivity by case
control status by time interval before PML diagnosis were dis-
played by box plots and levels of antibodies to BKPyV 1, BKPyV 4,
and JCPyV between cases and controls at each time interval were
compared by Wilcoxon test. Logistic regression with generalized
estimating equation and matched case-control-pair number as
strata was used to investigate the relationship between PML and
levels of log 2-transformed BKPyV 1, BKPyV 4, and JCPyV OD
values by using SAS GENMOD procedure (SAS Institute, Cary, North
Carolina, USA). Separate univariate and multivariate analyses
(adjusted for age at diagnosis, CD4þ T-cell counts, and log 2
transformed JCPyV OD value) were conducted for antibodies to
BKPyV 1 and BKPyV 4. Another multivariate logistic model was
also performed including all possible predictors: age at diagnosis,
CD4þ T-cell counts, and log 2-transformed JCPyV, BKPyV 1, and
BKPyV 4 OD values. A Wilcoxon test was used to compare differ-
ences between cases and controls in percent seroreactivity blocked
by pre-incubation with BKPyV 4 VLP antigen (percent blocked) at
1–1.5 year before PML. The proportion of samples from cases and
controls that were blocked by at least or more than 40% in the
competitive inhibition assay were compared by Fisher's exact test.
Conditional logistic regression, with adjustment for age and CD4þ
T-cell, was used to investigate the association between the percent
blocked and the risk of subsequent development of PML. Classiﬁ-
cation tree analysis predicting PML was performed by using Splus
software (TIBCO Spotﬁre Sþs 8.2, TIBCO Software Inc.). Predictors
in the classiﬁcation tree analysis included CD4þ T-cell count, and
OD values of BKPyV 1, BKPyV 4, and JCPyV seroreactivity where
the average value for each biomarker over 0.5–2 years before PML
was used. Exploratory pruning of trees was done by examining
deviance with addition of nodes and effects of pruning on mis-
classiﬁcation rate.Acknowledgments
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